Immune Response after Covid 19 Vaccination as an effort to prevent infection and Herd Immunity
Article Sidebar
Main Article Content
Abstract
Vaccination programs are one of the most cost-effective and efficient medical therapies in history. This study aims to elicit an immune response after the COVID-19 vaccination and the occurrence of herd immunity. This research is a literature review research by conducting journal searches carried out with the keys: immune response to Covid 19, Covid 19 Vaccination and Herd Immunity. Articles are collected using search engines such as google pubmed, schooler, EBSCO, Sciencedirect, and Proquest. The criteria for the articles used are those published in 2020 – 20232. The Covid 19 virus is a member of the Sarbecovirus subgenus and is distinguished by a stick-shaped spike protein that protrudes from the virion's surface. Global immunization initiatives boost immune systems. Immune cells and proteins that circulate in the body have the ability to provide protection from illness. Prior to immunization, antibodies from patients who had already been exposed to the virus resembled those produced following the first vaccination in healthy individuals. In people who were previously infected after the first vaccination, the level is the same as in people who were not infected after the second vaccination, booster administration has been shown to increase immunity with a 1.5 to 2-fold increase in titers and herd immunity is the only way to end the Covid 19 pandemic.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
References
Frederiksen LSF, Zhang Y, Foged C, and Thakur A, “The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies,” Front. Immunol., vol. 11, p. 1817, 2020.
LytrasT and Tsiodras S, “Lockdowns and the COVID-19 pandemic: What is the endgame?,” Scand. J. Public Health, vol. 49, no. 1, pp. 37–40, 2021.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, and Veesler D, “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell, vol. 181, no. 2, pp. 281-292.e6, 2020.
Lai CC, Shih TP, Ko WC, Tang HJ, and Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar; 55(3): 105924, doi: 10.1016/j.ijantimicag.2020.105924
Unicef. Immunization, Vaccines are the world's safest method to protect children from life-threatening diseases [cited on 2023 June 10] available https://www.unicef.org/immunization
Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A & Robertson DL. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic, Nature Microbiology volume 5, pages1408–1417 28 July 2020
Krause PR, 2021 “Considerations in boosting COVID-19 vaccine immune responses,” Lancet, vol. 398, no. 10308, pp. 1377–1380, 2021.
Reynolds S, “Lasting immunity found after recovery from COVID-19,” NIH Res. Matters, vol. 11, p. 6523, 2021.
Abdollahi A, Afsharyzad Y, Vaezi A and Meysamie A. Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity, Vaccines 2022, 10(10), 1708; https://doi.org/10.3390/vaccines10101708
Fontanet A and Cauchemez S, “COVID-19 herd immunity: where are we?,” Nat. Rev. Immunol., vol. 20, no. 10, pp. 583–584, 2020.
Randolph HE and Barreiro LB, “Herd Immunity: Understanding COVID-19,” Immunity, vol. 52, no. 5, pp. 737–741, 2020.
Hampton LM, Aggarwal R, Evans SJW, and Law B, “General determination of causation between Covid-19 vaccines and possible adverse events,” Vaccine, vol. 39, no. 10, p. 1478, 2021.
Jalkanen, Kolehmainen P , Häkkinen HK, Huttunen M , Tähtinen PA, Lundberg R , Maljanen S , Reinholm A, 2021 : “COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants,” Nat. Commun., vol. 12, no. 1, p. 3991, 2021.
Sternberg A and Naujokat C, “Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination,” Life Sci., vol. 257, p. 118056, 2020.
Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Frauke Muecksch F, Magdalena Rutkowska M, 2020 et al., “Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants,” Elife, vol. 9, p. e61312, 2020.
Kadkhoda K, “Herd immunity to COVID-19: alluring and elusive,” Am. J. Clin. Pathol., vol. 155, no. 4, pp. 471–472, 2021.
Hernandez RG, Hagen L, Walker K, O’Leary H, and Lengacher C, “The COVID-19 vaccine social media infodemic: healthcare providers’ missed dose in addressing misinformation and vaccine hesitancy,” Hum. Vaccin. Immunother., vol. 17, no. 9, pp. 2962–2964, Sep. 2021.
Khan YH , “Threat of COVID-19 vaccine hesitancy in Pakistan: the need for measures to neutralize misleading narratives,” Am. J. Trop. Med. Hyg., vol. 103, no. 2, p. 603, 2020.
Yan Q, Tang Y , Yan D , Wang J , Yang L , Yang X , Tang S, 2020 “Impact of media reports on the early spread of COVID-19 epidemic,” J. Theor. Biol., vol. 502, p. 110385, 2020.